×
About 4,220 results

ALLMedicine™ Pericardial Effusion Center

Research & Reviews  1,450 results

Intermediate risk pulmonary embolism concomitant with or without lung cancer: a wide sp...
https://doi.org/10.1080/10641963.2022.2093892
Clinical and Experimental Hypertension (New York, N.Y. : ... Jin YJ, Jin YF et. al.

Jun 30th, 2022 - We aimed to investigate the differences in clinical features between pulmonary embolism (PE) patients concomitant with lung cancer and without lung cancer (LC) and gain further understanding of the impact of lung cancer on pulmonary embolism. This...

Giant coronary aneurysms in an infant: Dilemma of MIS-C.
https://doi.org/10.1111/echo.15408
Echocardiography (Mount Kisco, N.Y.); Drury A, Wold K et. al.

Jun 26th, 2022 - COVID-19 related multisystem inflammatory syndrome in children (MIS-C) can present with cardiovascular complications like shock, arrhythmias, pericardial effusion, and coronary artery dilatation. The majority of MIS-C associated coronary artery ab...

Predictive risk score of respiratory complications in children with mediastinal tumors:...
https://doi.org/10.1002/cam4.4972
Cancer Medicine; Honda M, Yuki A et. al.

Jun 25th, 2022 - The aim of this study was to examine risk factors of respiratory complications at the diagnosis and establish an algorithm of clinical management in children and adolescents with mediastinal tumors. We retrospectively collected clinical informatio...

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

Jun 24th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

When is tamponade not an echocardiographic diagnosis… Or is it ever?
https://doi.org/10.1111/echo.15361
Echocardiography (Mount Kisco, N.Y.); Dragoi L, Teijeiro-Paradis R et. al.

Jun 24th, 2022 - Although cardiac tamponade remains a clinical diagnosis, echocardiography is an essential tool to detect fluid in the pericardial space. Interpretation of echocardiographic findings and assessment of physiologic and hemodynamic consequences of a p...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  71 results

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

Jun 24th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Full Early Atrial Diagnostics in Single Chamber ICD Patients Using the DX Lead and Home Monitoring in Brazil.
https://clinicaltrials.gov/ct2/show/NCT04869527

Jun 16th, 2022 - To demonstrate the value and benefits of BIOTRONIK's exclusive DX technology in assessing the incidence of supraventricular arrhythmias, mainly atrial fibrillation (AF), in patients with an indication for single chamber ICDs. Effects of the DX tec...

Artificial Intelligence-aimed Point-of-care Ultrasound Image Interpretation System
https://clinicaltrials.gov/ct2/show/NCT04876157

Jun 7th, 2022 - Ultrasound is a non-invasive and non-radiated diagnostic tool in the emergency and critical care settings. In clinical practice, timely interpretation of sonographic images to facilitate decision-making is essential. However, it depends on operato...

COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry
https://clinicaltrials.gov/ct2/show/NCT04661657

Jun 6th, 2022 - This is a pilot study aiming to collect preliminary data on cardiac imaging (CMR and TTE) in outpatients who recovered from COVID-19. CMR offers the unique ability to comprehensively characterize myocardial tissue and assess the heart's structure ...

Timing for Removal of Chest Tubes in Adult Cardiac Surgery
https://clinicaltrials.gov/ct2/show/NCT04487262

Jun 1st, 2022 - Rationale: Evidence regarding the timing of chest tube removal after cardiac surgery is sparse. The timing of chest tubes removal constitutes a balancing act between risk of retained blood syndrome, infection, patient discomfort and opioid-related...

see more →

News  153 results

New Real-World Data Bolster Safety of Watchman FLX in LAAO
https://www.medscape.com/viewarticle/973262

May 2nd, 2022 - In-hospital safety and procedural outcomes for percutaneous left atrial appendage (LAA) closure are substantially better with the Watchman FLX device than with its predecessor, new research shows. Data from more than 50,000 patients in the Nationa...

Small Leaks After LAAO Linked to Thromboembolism, Bleeding
https://www.medscape.com/viewarticle/971709

Apr 6th, 2022 - Small leaks after left atrial appendage occlusion (LAAO) with the Watchman 2.5 device were common and associated with more thromboembolic and bleeding events, new research shows. One in four patients (25.8%) in a national registry had a small leak...

Real-world data support safety of newer LAA device
https://www.mdedge.com/cardiology/article/252750/arrhythmias-ep/real-world-data-support-safety-newer-laa-device
Ted Bosworth

Mar 15th, 2022 - More than 18 months after the Watchman FLX device was licensed by the Food and Drug Administration for closure of the left atrial appendage (LAA), a prospective analysis of registry data presented at CRT 2022, sponsored by MedStar Heart & Vascular.

Hair Loss Drugs Ranked in Order of Efficacy
https://www.medpagetoday.com/dermatology/generaldermatology/97062

Feb 7th, 2022 - The 5-alpha reductase inhibitor (5-ARI) dutasteride (Avodart) likely is the most efficacious among the three drugs currently used to treat androgenetic alopecia (AGA), or male pattern baldness, according to a network meta-analysis. Overall rank fo...

Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC
https://www.onclive.com/view/published-entrectinib-data-demonstrate-encouraging-responses-in-ros1-nsclc

Oct 6th, 2021 - Robert C. Doebele, MD, PhD Treatment with entrectinib (Rozlytrek) led to an overall response rate (ORR) of 77% and a median duration of response (DOR) of 24.6 months in patients with ROS1 fusion—positive non–small cell lung cancer (NSCLC), accord...

see more →

Patient Education  5 results see all →